Viking Therapeutics is trading at $24.73, down 4.28%, with reported biotech-sector weakness the likeliest immediate context.
- No new company-specific announcement explaining the October 23 decline surfaced in available reports.
- Recent coverage describes month-long pressure tied to dilution concerns after a $575 million financing and competition in obesity treatments; these are background factors, not confirmed catalysts for this session.
- Weaker broader-market sentiment is also accompanying the decline.